Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.
Identifieur interne : 000846 ( PubMed/Corpus ); précédent : 000845; suivant : 000847Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.
Auteurs : Hung-Chang Chen ; Noémie Joalland ; John S. Bridgeman ; Fouad S. Alchami ; Ulrich Jarry ; Mohd Wajid A. Khan ; Luke Piggott ; Yasmin Shanneik ; Jianqiang Li ; Marco J. Herold ; Thomas Herrmann ; David A. Price ; Awen M. Gallimore ; Richard W. Clarkson ; Emmanuel Scotet ; Bernhard Moser ; Matthias EberlSource :
- Immunology and cell biology [ 1440-1711 ] ; 2017.
Abstract
The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC-restricted γδ T cells and antigen-specific CD8(+) T cells. Stable lines with characteristics of breast CSC-like cells were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their CD44(hi) CD24(lo) GD2(+) phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non-adherent conditions, as well as their potent tumorigenicity, self-renewal and differentiation in xenografted mice. The resistance of CSC-like cells to γδ T cells could be overcome by inhibition of farnesyl pyrophosphate synthase (FPPS) through pretreatment with zoledronate or with FPPS-targeting short hairpin RNA. γδ T cells induced upregulation of MHC class I and CD54/ICAM-1 on CSC-like cells and thereby increased the susceptibility to antigen-specific killing by CD8(+) T cells. Alternatively, γδ T-cell responses could be specifically directed against CSC-like cells using the humanised anti-GD2 monoclonal antibody hu14.18K322A. Our findings identify a powerful synergism between MHC-restricted and non-MHC-restricted T cells in the eradication of cancer cells including breast CSCs. Our research suggests that novel immunotherapies may benefit from a two-pronged approach combining γδ T-cell and CD8(+) T-cell targeting strategies that triggers effective innate-like and tumour-specific adaptive responses.
DOI: 10.1038/icb.2017.21
PubMed: 28356569
Links to Exploration step
pubmed:28356569Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.</title><author><name sortKey="Chen, Hung Chang" sort="Chen, Hung Chang" uniqKey="Chen H" first="Hung-Chang" last="Chen">Hung-Chang Chen</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Joalland, Noemie" sort="Joalland, Noemie" uniqKey="Joalland N" first="Noémie" last="Joalland">Noémie Joalland</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bridgeman, John S" sort="Bridgeman, John S" uniqKey="Bridgeman J" first="John S" last="Bridgeman">John S. Bridgeman</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Alchami, Fouad S" sort="Alchami, Fouad S" uniqKey="Alchami F" first="Fouad S" last="Alchami">Fouad S. Alchami</name><affiliation><nlm:affiliation>Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Jarry, Ulrich" sort="Jarry, Ulrich" uniqKey="Jarry U" first="Ulrich" last="Jarry">Ulrich Jarry</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Khan, Mohd Wajid A" sort="Khan, Mohd Wajid A" uniqKey="Khan M" first="Mohd Wajid A" last="Khan">Mohd Wajid A. Khan</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Piggott, Luke" sort="Piggott, Luke" uniqKey="Piggott L" first="Luke" last="Piggott">Luke Piggott</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Shanneik, Yasmin" sort="Shanneik, Yasmin" uniqKey="Shanneik Y" first="Yasmin" last="Shanneik">Yasmin Shanneik</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Jianqiang" sort="Li, Jianqiang" uniqKey="Li J" first="Jianqiang" last="Li">Jianqiang Li</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Herold, Marco J" sort="Herold, Marco J" uniqKey="Herold M" first="Marco J" last="Herold">Marco J. Herold</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Herrmann, Thomas" sort="Herrmann, Thomas" uniqKey="Herrmann T" first="Thomas" last="Herrmann">Thomas Herrmann</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Price, David A" sort="Price, David A" uniqKey="Price D" first="David A" last="Price">David A. Price</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gallimore, Awen M" sort="Gallimore, Awen M" uniqKey="Gallimore A" first="Awen M" last="Gallimore">Awen M. Gallimore</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Clarkson, Richard W" sort="Clarkson, Richard W" uniqKey="Clarkson R" first="Richard W" last="Clarkson">Richard W. Clarkson</name><affiliation><nlm:affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Scotet, Emmanuel" sort="Scotet, Emmanuel" uniqKey="Scotet E" first="Emmanuel" last="Scotet">Emmanuel Scotet</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moser, Bernhard" sort="Moser, Bernhard" uniqKey="Moser B" first="Bernhard" last="Moser">Bernhard Moser</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Eberl, Matthias" sort="Eberl, Matthias" uniqKey="Eberl M" first="Matthias" last="Eberl">Matthias Eberl</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28356569</idno><idno type="pmid">28356569</idno><idno type="doi">10.1038/icb.2017.21</idno><idno type="wicri:Area/PubMed/Corpus">000846</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000846</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.</title><author><name sortKey="Chen, Hung Chang" sort="Chen, Hung Chang" uniqKey="Chen H" first="Hung-Chang" last="Chen">Hung-Chang Chen</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Joalland, Noemie" sort="Joalland, Noemie" uniqKey="Joalland N" first="Noémie" last="Joalland">Noémie Joalland</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bridgeman, John S" sort="Bridgeman, John S" uniqKey="Bridgeman J" first="John S" last="Bridgeman">John S. Bridgeman</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Alchami, Fouad S" sort="Alchami, Fouad S" uniqKey="Alchami F" first="Fouad S" last="Alchami">Fouad S. Alchami</name><affiliation><nlm:affiliation>Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Jarry, Ulrich" sort="Jarry, Ulrich" uniqKey="Jarry U" first="Ulrich" last="Jarry">Ulrich Jarry</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Khan, Mohd Wajid A" sort="Khan, Mohd Wajid A" uniqKey="Khan M" first="Mohd Wajid A" last="Khan">Mohd Wajid A. Khan</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Piggott, Luke" sort="Piggott, Luke" uniqKey="Piggott L" first="Luke" last="Piggott">Luke Piggott</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Shanneik, Yasmin" sort="Shanneik, Yasmin" uniqKey="Shanneik Y" first="Yasmin" last="Shanneik">Yasmin Shanneik</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Jianqiang" sort="Li, Jianqiang" uniqKey="Li J" first="Jianqiang" last="Li">Jianqiang Li</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Herold, Marco J" sort="Herold, Marco J" uniqKey="Herold M" first="Marco J" last="Herold">Marco J. Herold</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Herrmann, Thomas" sort="Herrmann, Thomas" uniqKey="Herrmann T" first="Thomas" last="Herrmann">Thomas Herrmann</name><affiliation><nlm:affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Price, David A" sort="Price, David A" uniqKey="Price D" first="David A" last="Price">David A. Price</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gallimore, Awen M" sort="Gallimore, Awen M" uniqKey="Gallimore A" first="Awen M" last="Gallimore">Awen M. Gallimore</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Clarkson, Richard W" sort="Clarkson, Richard W" uniqKey="Clarkson R" first="Richard W" last="Clarkson">Richard W. Clarkson</name><affiliation><nlm:affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Scotet, Emmanuel" sort="Scotet, Emmanuel" uniqKey="Scotet E" first="Emmanuel" last="Scotet">Emmanuel Scotet</name><affiliation><nlm:affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moser, Bernhard" sort="Moser, Bernhard" uniqKey="Moser B" first="Bernhard" last="Moser">Bernhard Moser</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Eberl, Matthias" sort="Eberl, Matthias" uniqKey="Eberl M" first="Matthias" last="Eberl">Matthias Eberl</name><affiliation><nlm:affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Immunology and cell biology</title><idno type="eISSN">1440-1711</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC-restricted γδ T cells and antigen-specific CD8(+) T cells. Stable lines with characteristics of breast CSC-like cells were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their CD44(hi) CD24(lo) GD2(+) phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non-adherent conditions, as well as their potent tumorigenicity, self-renewal and differentiation in xenografted mice. The resistance of CSC-like cells to γδ T cells could be overcome by inhibition of farnesyl pyrophosphate synthase (FPPS) through pretreatment with zoledronate or with FPPS-targeting short hairpin RNA. γδ T cells induced upregulation of MHC class I and CD54/ICAM-1 on CSC-like cells and thereby increased the susceptibility to antigen-specific killing by CD8(+) T cells. Alternatively, γδ T-cell responses could be specifically directed against CSC-like cells using the humanised anti-GD2 monoclonal antibody hu14.18K322A. Our findings identify a powerful synergism between MHC-restricted and non-MHC-restricted T cells in the eradication of cancer cells including breast CSCs. Our research suggests that novel immunotherapies may benefit from a two-pronged approach combining γδ T-cell and CD8(+) T-cell targeting strategies that triggers effective innate-like and tumour-specific adaptive responses.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28356569</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>30</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1711</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Immunology and cell biology</Title><ISOAbbreviation>Immunol. Cell Biol.</ISOAbbreviation></Journal><ArticleTitle>Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.</ArticleTitle><Pagination><MedlinePgn>620-629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/icb.2017.21</ELocationID><Abstract><AbstractText>The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC-restricted γδ T cells and antigen-specific CD8(+) T cells. Stable lines with characteristics of breast CSC-like cells were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their CD44(hi) CD24(lo) GD2(+) phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non-adherent conditions, as well as their potent tumorigenicity, self-renewal and differentiation in xenografted mice. The resistance of CSC-like cells to γδ T cells could be overcome by inhibition of farnesyl pyrophosphate synthase (FPPS) through pretreatment with zoledronate or with FPPS-targeting short hairpin RNA. γδ T cells induced upregulation of MHC class I and CD54/ICAM-1 on CSC-like cells and thereby increased the susceptibility to antigen-specific killing by CD8(+) T cells. Alternatively, γδ T-cell responses could be specifically directed against CSC-like cells using the humanised anti-GD2 monoclonal antibody hu14.18K322A. Our findings identify a powerful synergism between MHC-restricted and non-MHC-restricted T cells in the eradication of cancer cells including breast CSCs. Our research suggests that novel immunotherapies may benefit from a two-pronged approach combining γδ T-cell and CD8(+) T-cell targeting strategies that triggers effective innate-like and tumour-specific adaptive responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hung-Chang</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joalland</LastName><ForeName>Noémie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche 6299, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridgeman</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alchami</LastName><ForeName>Fouad S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarry</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche 6299, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Mohd Wajid A</ForeName><Initials>MWA</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piggott</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanneik</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jianqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herold</LastName><ForeName>Marco J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Immunity Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallimore</LastName><ForeName>Awen M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Immunity Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarkson</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scotet</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>INSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche 6299, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Immunity Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberl</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9390-5348</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Immunity Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunol Cell Biol</MedlineTA><NlmUniqueID>8706300</NlmUniqueID><ISSNLinking>0818-9641</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 Jun 1;182(11):7287-96</RefSource><PMID Version="1">19454726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2003 Aug 4;198(3):433-42</RefSource><PMID Version="1">12900519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 May 10;32(14):1445-52</RefSource><PMID Version="1">24711551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):4968-73</RefSource><PMID Version="1">23479608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2016 Mar;27(3):379-90</RefSource><PMID Version="1">26681681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Oct 1;17(19):6174-84</RefSource><PMID Version="1">21856769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genes Dev. 2001 Jan 1;15(1):50-65</RefSource><PMID Version="1">11156605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2011 Sep 14;13(5):R88</RefSource><PMID Version="1">21914219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 Oct;12(11):991-2</RefSource><PMID Version="1">21968221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2013 Jan;139(1):159-70</RefSource><PMID Version="1">23001491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2013 Mar 1;190(5):2381-90</RefSource><PMID Version="1">23345327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Mol Immunol. 2013 Jan;10(1):35-41</RefSource><PMID Version="1">23241899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2016 Dec;22(12 ):1402-1410</RefSource><PMID Version="1">27775706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2013 Dec;43(12):3159-62</RefSource><PMID Version="1">24136367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2015 Nov;15(11):683-91</RefSource><PMID Version="1">26449179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2013;18(8):e22-3</RefSource><PMID Version="1">23986344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2011;29:235-71</RefSource><PMID Version="1">21219185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2010 May 11;107(19):8730-5</RefSource><PMID Version="1">20413723</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2013 Sep 10;338(1):57-62</RefSource><PMID Version="1">22554712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2015 Mar 25;7(280):280ps7</RefSource><PMID Version="1">25810311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2015 Mar 1;194(5):2390-8</RefSource><PMID Version="1">25637025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource><PMID Version="1">21376230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2011 Jul 15;187(2):1031-8</RefSource><PMID Version="1">21670311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2012 Mar 22;12(4):269-81</RefSource><PMID Version="1">22437939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Immunol. 2016;130:279-94</RefSource><PMID Version="1">26923004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bone Miner Res. 2013 Mar;28(3):464-71</RefSource><PMID Version="1">23074158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2012 Jul;42(7):1668-76</RefSource><PMID Version="1">22806069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2016 Mar 30;5(6):e1168554</RefSource><PMID Version="1">27471644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2008 May 16;133(4):704-15</RefSource><PMID Version="1">18485877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2001 Jun 15;166(12):7190-9</RefSource><PMID Version="1">11390467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Immunol. 2014 Aug 14;5:372</RefSource><PMID Version="1">25177320</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 Jun 15;182(12):8118-24</RefSource><PMID Version="1">19494338</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Dec 1;69(23 ):8886-93</RefSource><PMID Version="1">19903840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Jun 15;73(12):3489-93</RefSource><PMID Version="1">23740771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2009 Oct;9(10):704-16</RefSource><PMID Version="1">19859065</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Mar 15;73(6):1981-92</RefSource><PMID Version="1">23378344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2015 Apr 3;348(6230):62-8</RefSource><PMID Version="1">25838374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunother. 2012 Oct;35(8):598-606</RefSource><PMID Version="1">22996365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2012 Feb 15;188(4):1708-16</RefSource><PMID Version="1">22250090</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2307-12</RefSource><PMID Version="1">19171897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Immunol. 2014 Jul 23;5:344</RefSource><PMID Version="1">25101086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2009 Sep;1176:154-69</RefSource><PMID Version="1">19796244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18507-12</RefSource><PMID Version="1">19017805</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Feb 1;16(3):800-13</RefSource><PMID Version="1">20103663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2010 Jan 15;70(2):697-708</RefSource><PMID Version="1">20068175</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 May 14;113(20):4875-84</RefSource><PMID Version="1">19278954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 2011 Oct;91(10):1502-13</RefSource><PMID Version="1">21691263</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Immunother. 2012 Jul;61(7):979-89</RefSource><PMID Version="1">22120758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2014 Jan 1;3(1):e27572</RefSource><PMID Version="1">24734216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2012 Jun;122(6):2066-78</RefSource><PMID Version="1">22585577</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28356569</ArticleId><ArticleId IdType="pii">icb201721</ArticleId><ArticleId IdType="doi">10.1038/icb.2017.21</ArticleId><ArticleId IdType="pmc">PMC5550559</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000846 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000846 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28356569
|texte= Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8(+) T cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28356569" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |